Title:
PLASMINOGEN ACTIVATOR TO PREVENT CORNEAL AND SUBEPITHELIAL HAZE AFTER LASER VISION CORRECTION SURGERY
Document Type and Number:
WIPO Patent Application WO2002030444
Kind Code:
A3
Abstract:
The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, tissue plasminogen activator, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.
More Like This:
Inventors:
SILVER DAVID M (US)
CSUTAK ADRIENNE (HU)
BERTA ANDRAS (HU)
TOZSER JOZSEF (HU)
CSUTAK ADRIENNE (HU)
BERTA ANDRAS (HU)
TOZSER JOZSEF (HU)
Application Number:
PCT/US2001/031849
Publication Date:
March 20, 2003
Filing Date:
October 12, 2001
Export Citation:
Assignee:
UNIV JOHNS HOPKINS (US)
SILVER DAVID M (US)
CSUTAK ADRIENNE (HU)
BERTA ANDRAS (HU)
TOZSER JOZSEF (HU)
SILVER DAVID M (US)
CSUTAK ADRIENNE (HU)
BERTA ANDRAS (HU)
TOZSER JOZSEF (HU)
International Classes:
A61K38/16; A61K38/43; A61K38/00; A61K38/48; A61K38/49; A61P27/02; A61P27/12; A61P41/00; A61P43/00; (IPC1-7): A61K38/49; A61P41/00
Domestic Patent References:
| WO2000066139A2 | 2000-11-09 |
Foreign References:
| DE19901594A1 | 2000-08-10 |
Other References:
LOFFLER K U ET AL: "[Success and complications of rTPA treatment of the anterior eye segment]. Erfolge und Komplikationen der rTPA-Behandlung am vorderen Augenabschnitt.", OPHTHALMOLOGE, (1997 JAN) 94 (1) 50-2., XP002225721
O'BRART D P ET AL: "The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy. A prospective, randomized, observer-masked study.", OPHTHALMOLOGY, (1994 SEP) 101 (9) 1565-74., XP001053299
LOHMANN C P ET AL: "Plasmin- and plasminogen - activator inhibitors after excimer laser photorefractive keratectomy: new concept in prevention of postoperative myopic regression and haze.", REFRACTIVE AND CORNEAL SURGERY, (1993 JUL-AUG) 9 (4) 300-2. REF: 22, XP001053383
CSUTAK, A. (1) ET AL: "Plasminogen activator activity in rabbit tears after excimer laser photorefractive keratectomy.", IOVS, (MARCH 15, 2000) VOL. 41, NO. 4, PP. S69. MEETING INFO.: ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY. FORT LAUDERDALE, FLORIDA, USA APRIL 30-MAY 05, 2000 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY., XP008011727
O'BRART D P ET AL: "The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy. A prospective, randomized, observer-masked study.", OPHTHALMOLOGY, (1994 SEP) 101 (9) 1565-74., XP001053299
LOHMANN C P ET AL: "Plasmin- and plasminogen - activator inhibitors after excimer laser photorefractive keratectomy: new concept in prevention of postoperative myopic regression and haze.", REFRACTIVE AND CORNEAL SURGERY, (1993 JUL-AUG) 9 (4) 300-2. REF: 22, XP001053383
CSUTAK, A. (1) ET AL: "Plasminogen activator activity in rabbit tears after excimer laser photorefractive keratectomy.", IOVS, (MARCH 15, 2000) VOL. 41, NO. 4, PP. S69. MEETING INFO.: ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY. FORT LAUDERDALE, FLORIDA, USA APRIL 30-MAY 05, 2000 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY., XP008011727
Download PDF: